EGFR and non-small cell lung carcinoma: The first-generation tyrosine kinase inhibitors (TKIs, e.g., erlotinib and gefitinib) have shown to significantly prolong the progression-free survival of NSCLC patients harboring EGFR mutations, primarily exon 19 deletion and exon 21 L858R substitution mutations [23,24].